Jay Gertz
@GertzLab
Followers
533
Following
772
Media
27
Statuses
347
Shameless promotion of our amazing gene regulation/cancer epigenetics work
Salt Lake City, UT
Joined October 2017
Glad to share our latest work on The EstroGene2.0 database for endocrine therapy response and resistance in breast cancer models, now published in @Nature_NPJ #npjBCancer, https://t.co/DSRDgcsTOP, with the super-multifunctional browser
2
6
14
We thank NCI for supporting our work in 3D cancer genomics! This work was led by our grad student Katie Mortenson, co-supervised by K-T Varley, with close collaborations from Yang Liu, @GertzLab , and @Sven_Bailey.
3
4
21
Our latest Review is live! Thanks to @GertzLab and @RMJesel for your help and @EndoSocJournals for publishing!
academic.oup.com
Abstract. Annual breast cancer (BCa) deaths have declined since its apex in 1989 concomitant with widespread adoption of hormone therapies that target estr
2
4
19
This excellent review on estrogen receptor alpha mutations, truncations, heterodimers, and therapies, goes into the history of ERα, current research unlocking unknown aspects of ERα signaling, and future directions of ESR1 investigation @RMJesel @GertzLab
https://t.co/16TTxTBI9m
1
11
35
Our work on how enhancers impact estrogen transcription timing and noise is now out in @CellGenomics! Thanks to everyone that helped out on this project! https://t.co/1JrlEoQdTv
@tweeterginley @xyzxiaoyang
cell.com
Through temporally resolved single-cell analysis of transcriptional responses to estrogen, Ginley-Hidinger et al. discovered that the presence of multiple estrogen-receptor alpha-bound enhancers is...
The latest @GertzLab preprint was just posted. It was a great group effort led by @tweeterginley with help from @xyzxiaoyang lab and John Lis’ lab. In this study, we explored how regulatory elements influence gene expression timing and noise in response to estrogen 1/
0
17
34
Our latest review article on estrogen receptor targeted therapies in breast cancer has been published!
academic.oup.com
Abstract. Annual breast cancer (BCa) deaths have declined since its apex in 1989 concomitant with widespread adoption of hormone therapies that target estr
2
10
27
We are recruiting! Time to recirculate this work since there’s still so much to do. If you have expertise in DNA damage repair #DDR and are looking for a postdoctoral position where you can lead clinically-relevant discoveries, please don’t hesitate to reach out. @KUMedCenter
I am proud to share with you our recently published paper showing that obesity promotes breast epithelium DNA damage in women carrying a germline mutation in BRCA1 or BRCA2
0
9
33
This week is National #PostdocAppreciationWeek. Zannel Blanchard, PhD (@xedbee) is a postdoctoral fellow in the Welm lab. She explains the role of a postdoc, what inspired her to become a cancer researcher, and why she loves working here. #HCIproud
0
6
25
Want to work in the heart of Dublin where cutting-edge research meets a super friendly lab environment? 🍀 Dive into the world of breast cancer brain metastasis with us. Dublin’s warmth and our team’s camaraderie await you! Apply now: https://t.co/TyuxbAHGUY
1
10
23
Endometrial cancer is the most common gynecological cancer and high levels of estrogen promote its development. Researchers at HCI, led by @xedbee and @GertzLab, have identified potential new treatment options for people with endometrial cancer. https://t.co/IvkwCF6e8w
0
11
31
My pleasure to have officiated the Gordon Conference Hormone Dependent Cancers 2023 Breast Vs Prostate Football Match. The breast team emerged happy & victorious 4-2 🏆🍾 @MagnaniLab_ICR @oesterreichs @DanielFrigo @damirvareslija @dralexswarbrick @drmcrl @BevanLab @scottdehm
3
6
37
Our work characterizing ER hotspot mutations in endometrial cancer is out in MCR 🥳 The study highlighted allele-specific differences between ER-Y537S and ER-D538G mutations and identified potential therapeutic targets in this disease.
.@xedbee et al. show the ER-Y537S mutation mediates unique gene expression changes in #endometrialcancer, and identify CDK9 and NCOA3 as potential therapeutic targets. https://t.co/zSAjP0wnjr
@CraigRushPhD @SpencerArnesen @SigCris @Mattchles @hishammt @GertzLab
2
4
14
The second major publication from Zannel's PhD project in the @GertzLab is now published in Molecular Cancer Research. I'm thankful to have had the opportunity to help out on this work that further defines the effects of mutant Estrogen Receptor in #endometrialcancer
.@xedbee et al. show the ER-Y537S mutation mediates unique gene expression changes in #endometrialcancer, and identify CDK9 and NCOA3 as potential therapeutic targets. https://t.co/zSAjP0wnjr
@CraigRushPhD @SpencerArnesen @SigCris @Mattchles @hishammt @GertzLab
0
2
8
.@xedbee et al. show the ER-Y537S mutation mediates unique gene expression changes in #endometrialcancer, and identify CDK9 and NCOA3 as potential therapeutic targets. https://t.co/zSAjP0wnjr
@CraigRushPhD @SpencerArnesen @SigCris @Mattchles @hishammt @GertzLab
0
1
8
Congrats to @SpencerArnesen and the rest of the team!! Great to see this fun project out in @NAR_Cancer_EIC!
Excited to share that our recent work regarding the role of microRNAs in ER mutant breast cancer is now out in NAR Cancer! A big thanks to all involved! @GertzLab @xedbee @OConnellLab @AlanaWelm
https://t.co/e2mM0KC6J8
0
1
4
It was an honor to be included as one of the @huntsmancancer Breast and Gynecologic Cancer Rising Stars yesterday alongside @KLawsonMichod, Dr. Alessandra Riggio, and Dr. Christopher Weil. It's great to see the impactful work being done on women's cancers.
1
2
2
I'm hiring! I have a 2-year funded #endometrial #cancer project for a postdoc with #organoid culture experience. Based in Brisbane with views like this, how can you say no? HMU if you have Qs about the role. Applications close 6th June https://t.co/e4UKipBK4s
0
23
33
Congrats to Ozlen, Brooke and the rest of the gang for getting this preprint up and the formal manuscript under peer review. https://t.co/0Kf7XtiIvh
biorxiv.org
Breast cancers are categorized into subtypes with distinctive therapeutic vulnerabilities based on expression of clinically targetable receptors and other genes that mimic cell types of the normal...
0
2
8
Thanks to excellent collaborators on this review exploring AR functions across multiple cancer types! @jaleo_leo @NR_IMPACT @TheEndoSociety @mikeslivefdn @LWellberg @ED_PhD_ @Nate_WilsonMD @OAlhalabiMD @mcquadeMDLAc @ShannonWestin et al https://t.co/zLlro5oiUZ
pubmed.ncbi.nlm.nih.gov
The androgen receptor (AR) is one of the oldest therapeutic targets in oncology and continues to dominate the treatment landscape for advanced prostate cancer, where nearly all treatment regimens...
5
12
59
Wu et al. show that ESR1 mutations promote FOXA1 localization to retinoid X receptor (RXR) motifs in ER+ #breastcancer, sensitizing breast cancer cells to RXR antagonists— https://t.co/efDnf6vgyd
@ancasey8 @GertzLab @jennifermxavier @Adrianvlee @oesterreichs
0
7
19